BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31719057)

  • 1. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.
    Ye J; Mills BN; Zhao T; Han BJ; Murphy JD; Patel AP; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    Cancer Immunol Res; 2020 Jan; 8(1):94-107. PubMed ID: 31719057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.
    Mills BN; Connolly KA; Ye J; Murphy JD; Uccello TP; Han BJ; Zhao T; Drage MG; Murthy A; Qiu H; Patel A; Figueroa NM; Johnston CJ; Prieto PA; Egilmez NK; Belt BA; Lord EM; Linehan DC; Gerber SA
    Cell Rep; 2019 Oct; 29(2):406-421.e5. PubMed ID: 31597100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer.
    Hegde S; Krisnawan VE; Herzog BH; Zuo C; Breden MA; Knolhoff BL; Hogg GD; Tang JP; Baer JM; Mpoy C; Lee KB; Alexander KA; Rogers BE; Murphy KM; Hawkins WG; Fields RC; DeSelm CJ; Schwarz JK; DeNardo DG
    Cancer Cell; 2020 Mar; 37(3):289-307.e9. PubMed ID: 32183949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.
    Duewell P; Steger A; Lohr H; Bourhis H; Hoelz H; Kirchleitner SV; Stieg MR; Grassmann S; Kobold S; Siveke JT; Endres S; Schnurr M
    Cell Death Differ; 2014 Dec; 21(12):1825-37. PubMed ID: 25012502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic body radiation combined with oncolytic vaccinia virus induces potent anti-tumor effect by triggering tumor cell necroptosis and DAMPs.
    Chen WY; Chen YL; Lin HW; Chang CF; Huang BS; Sun WZ; Cheng WF
    Cancer Lett; 2021 Dec; 523():149-161. PubMed ID: 34606928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
    Nam GH; Lee EJ; Kim YK; Hong Y; Choi Y; Ryu MJ; Woo J; Cho Y; Ahn DJ; Yang Y; Kwon IC; Park SY; Kim IS
    Nat Commun; 2018 Jun; 9(1):2165. PubMed ID: 29867097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
    Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
    Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
    Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    Lin C; Verma V; Lazenby A; Ly QP; Berim LD; Schwarz JK; Madiyalakan M; Nicodemus CF; Hollingsworth MA; Meza JL; Are C; Padussis J; Grem JL
    Am J Clin Oncol; 2019 Oct; 42(10):755-760. PubMed ID: 31513018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.
    Mills BN; Qiu H; Drage MG; Chen C; Mathew JS; Garrett-Larsen J; Ye J; Uccello TP; Murphy JD; Belt BA; Lord EM; Katz AW; Linehan DC; Gerber SA
    Clin Cancer Res; 2022 Jan; 28(1):150-162. PubMed ID: 34862242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas.
    Downs-Canner S; Zenati M; Boone BA; Varley PR; Steve J; Hogg ME; Zureikat A; Zeh HJ; Lee KK
    J Surg Oncol; 2015 Jul; 112(1):80-5. PubMed ID: 26153355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
    Blair AB; Kleponis J; Thomas DL; Muth ST; Murphy AG; Kim V; Zheng L
    J Clin Invest; 2019 Apr; 129(4):1742-1755. PubMed ID: 30747725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting both tumour-associated CXCR2
    Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
    Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.